Buy Pnc-27 Peptide

Direct Sourcing Summary: Sourcing PNC-27 for Preclinical Research

Principal investigators looking to buy PNC-27 peptide require high-purity analytical standards that deliver consistent, reproducible results in cell culture and biochemical assays. PNC-27 is a specialized membrane-active synthetic peptide designed exclusively for laboratory research investigating targeted cell membrane lysis and HDM-2 interaction pathways.

When you source PNC-27 peptide from PX1 Research, your facility receives lyophilized compound manufactured in compliance with strict USA quality control frameworks. Every batch is validated via high-performance liquid chromatography (RP-HPLC) and matrix-assisted laser desorption/ionization mass spectrometry (MALDI-TOF MS), backed by a downloadable, lot-specific Certificate of Analysis (COA) detailing exact chemical purity and low endotoxin levels.

Molecular Structure and Biochemical Overview of PNC-27

PNC-27 is a synthetic chimeric peptide comprising two distinct structural domains: an active HDM-2 (human double minute 2) binding domain derived from the p53 tumor suppressor protein (residues 12–26) coupled to a cell-penetrating peptide transmembrane sequence derived from penetratin (Antennapedia homeodomain). This specific engineering allows PNC-27 to interact with target cellular membranes with elevated conformational stability.

In structural biology models, the HDM-2-binding alpha-helical region retains high affinity for the hydrophobic cleft of HDM-2 proteins. By conjugating this sequence to a hydrophobic transmembrane leader peptide, researchers can evaluate how spatial orientation influences localized membrane disruption. Detailed analytical breakdowns of related constructs can be found within the PX1 research library.

Because synthetic peptide stability depends heavily on amino acid fidelity, PX1 Research utilizes solid-phase peptide synthesis (SPPS) under stringent manufacturing protocols. This ensures that the primary 32-amino-acid sequence of PNC-27 maintains its exact spatial conformation across reconstitutions, minimizing truncation products or sequence heterogeneity during critical in vitro experiments.

Primary Mechanism of Action: HDM-2 Binding and Transmembrane Pore Formation

Preclinical investigations demonstrate that the primary mechanism of PNC-27 involves targeted binding to membrane-bound HDM-2 co-receptors expressed on specific transformed cell lines. Unlike conventional small-molecule inhibitors that target intracellular HDM-2 to restore nuclear p53 transcriptional activity, PNC-27 targets HDM-2 localized specifically within the lipid bilayer of transformed cell membranes.

Upon binding to cell-surface HDM-2, in vitro data indicate that PNC-27 undergoes an amphipathic alpha-helical conformational shift. This structural alteration promotes oligomerization within the plasma membrane, resulting in rapid transmembrane pore formation. The physical formation of these non-specific pores leads to loss of membrane integrity, rapid extracellular ion influx, cell swelling, and catastrophic membrane rupture.

Biophysical characterization assays suggest that this pore-forming mechanism acts rapidly—often within minutes of exposure in cell culture models—distinguishing PNC-27 from traditional apoptosis-inducing compounds. Further mechanisms of membrane-active cancer peptides showcase how membrane-targeted architecture bypasses classic intracellular resistance pathways.

p53-Independent Lytic Pathways in Preclinical Literature

A critical finding in published preclinical studies is that PNC-27 induces cell lysis independently of the functional p53 pathway. Traditional targeted therapies rely on intact p53 signaling to trigger programmed cell death (apoptosis). However, many transformed lines harbor mutated, truncated, or completely deleted p53 genes, rendering them resistant to standard apoptotic triggers.

Because PNC-27 relies strictly on the physical interaction with surface-localized HDM-2 and subsequent pore formation, cell culture assays confirm its cytotoxicity against p53-homozygous null, mutant, and wild-type transformed cell lines alike. The cell death pathway triggered by PNC-27 is classified morphologically and biochemically as necrosis rather than apoptosis, characterized by rapid ATP depletion, swelling, and lack of caspase-3 activation.

Comparative assays published in academic literature highlight that non-transformed, healthy cell lines typically express negligible levels of surface-bound HDM-2. Consequently, in vitro studies report that PNC-27 displays negligible binding affinity and membranolytic activity when incubated with normal human fibroblasts or blood mononuclear cells under identical experimental conditions.

Comparative Analysis: PNC-27 vs. PNC-28 and Nutlin-3a

When establishing experimental designs targeting the HDM-2/p53 axis, researchers frequently compare PNC-27 against structural analogs and small-molecule antagonists. Understanding the distinct biochemical profiles of these compounds is essential for selecting the appropriate laboratory reagent.

For instance, PNC-28 is a closely related chimeric peptide containing p53 residues 17–26 attached to the same penetratin cell-penetrating sequence. While both peptides target membrane-bound HDM-2 to induce rapid necrosis, PNC-28 features a shorter p53-derived binding fragment, which researchers evaluate to compare binding kinetics, membrane-insertion velocities, and peptide stability in serum-containing media. Comprehensive structural comparisons are detailed in our guide on p53-hdm2 pathway peptides.

In contrast, non-peptide small molecules such as Nutlin-3a function through an entirely different mechanism. Nutlin-3a competitively inhibits the intracellular HDM-2/p53 interaction inside the nucleus, preventing p53 degradation and forcing the cell into classical p53-dependent apoptotic pathways. Researchers studying transformed cells with p53 loss-of-function mutations often utilize PNC-27 peptide instead of Nutlin-3a, as Nutlin-3a is ineffective in p53-null environments, whereas PNC-27 operates via physical pore formation regardless of nuclear p53 status.

Laboratory Reconstitution and Storage Protocols

To maintain the structural integrity and biological activity of lyophilized PNC-27, laboratory personnel must follow standard biochemical handling procedures. PNC-27 is supplied as a sterile, lyophilized cake that should be stored at -20°C or -80°C upon receipt to prevent thermal degradation.

Reconstitution should be performed under a laminar flow hood using sterile, research-grade solvents. For basic cell culture applications, reconstitute the peptide in sterile bacteriostatic water or sterile phosphate-buffered saline (PBS, pH 7.4). If initial dissolution proves difficult due to the amphipathic nature of the penetratin domain, brief gentle sonication or the addition of a minimal volume of dimethyl sulfoxide (DMSO, <0.1% final concentration in assay) may be employed.

For detailed step-by-step instructions on handling hydrophobic and amphipathic sequences, consult our standard peptide reconstitution protocol. Reconstituted stock solutions should be aliquoted into polypropylene microcentrifuge tubes to prevent adsorption to glass surfaces and stored at -80°C. Avoid repeated freeze-thaw cycles, which can cause aggregation or peptide cleavage.

Analytical Purity Verification: RP-HPLC, Mass Spectrometry, and Endotoxin Standards

In vitro data reliability is heavily dependent on compound purity. Contaminants such as truncated peptide sequences, residual synthesis reagents, or bacterial endotoxins can confound cell culture assays, alter cell viability readings, or induce non-specific inflammatory responses in cellular models.

PX1 Research enforces strict analytical quality control for every lot of PNC-27 manufactured in our USA facilities. Purity verification involves two primary orthogonal methods:

1. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC): Measures chemical purity by separating the main sequence from synthesis byproducts. PX1 guarantees a minimum purity threshold of 98% for research grade lots. 2. Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-TOF MS): Confirms precise molecular weight and amino acid composition, verifying that no sequence errors occurred during synthesis.

Additionally, because endotoxins (lipopolysaccharides) can directly alter membrane permeability and induce non-specific cell death in culture, every lot undergoes Chromogenic LAL (Limulus Amebocyte Lysate) testing. PX1 ensures endotoxin levels remain strictly below <0.01 EU/mg, providing clean experimental conditions for sensitive cell line assays. Technical protocols for evaluating purity data are available in our technical review on peptide purity HPLC analysis.

Why Source Research Compounds from PX1 Research

Navigating vendor quality can be challenging for research institutions. PX1 Research operates as a dedicated USA supplier tailored specifically to academic laboratories, biotechnology firms, and institutional research facilities. We do not supply compounds for human use or consumer applications.

Key operational differentiators of PX1 Research include:

- Domestic Synthesis: All peptides are produced in GMP-compliant, USA-based facilities using state-of-the-art solid-phase synthesis instruments. - Independent Verification: Every batch is validated by an ISO 17025 accredited third-party testing laboratory prior to release. - Full Traceability: Every vial is assigned a unique lot number matching its downloadable, public Certificate of Analysis. - Rapid Dispatch: Direct shipping from our CA and AZ logistics hubs with same-day dispatch for orders placed before cutoff times.

For institutional purchasing departments managing high-volume screening projects, PX1 Research provides streamlined procurement through our wholesale lab accounts program, guaranteeing lot consistency across multi-phase studies.